Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core High Dividend ETF (HDV) vs Zoetis Inc (ZTS) Price & Performance

iShares Core High Dividend ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

iShares Core High Dividend ETF vs Zoetis Inc — how do they compare? iShares Core High Dividend ETF trades at $28.75 (market cap $14.68B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.1× iShares Core High Dividend ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Zoetis Inc for 70 Days on average.

HDVZTS
Market Cap
$14.68B$30.20B
Volume
2,925,5626,175,327
52-Week High
$29.93$147.53
52-Week Low
$23.64$69.09
Typical Hold Time
117 Days70 Days
Sector
—Health
Enterprise Value
—$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core High Dividend ETF

HDV (iShares Core High Dividend ETF) trades at $28.71, up 1.52% with a bullish technical signal. Recent sector rebalancing reduced healthcare exposure by nearly half while increasing energy, staples, and utilities, creating concentration risk with 62% in three sectors. The ETF yields approximately 3% but faces questions about whether this compensates for reduced diversification. Technical indicators show strong momentum with RSI at 77.74 suggesting potential overbought conditions.

The outlook remains cautiously optimistic given HDV's 2026 outperformance against the S&P 500, though the concentrated sector allocation and moderate yield present both opportunity and risk. Investors should weigh the fund's recent structural changes against its dividend income generation capabilities in a rising rate environment.

Zoetis Inc

Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.

Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HDV
79% Buy21% Sell
Avg holding period · 117 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About iShares Core High Dividend ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.

Read more on HDV →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →